On 28 May 2026, Amsterdam (Tolhuistuin) RegMed XB was prominently represented at the Nationaal Groeifonds (NGF) Jaarevent 2026, where Chair of the Supervisory Board Conny Helder took part in a panel discussion on how major public investments can translate into sustainable impact for the Netherlands.

The early bird registration period for the RegMed XB Annual Conference is coming to an end. With only a few days remaining, this is the last opportunity to register at the reduced early bird rate.

Within the RegMed XB consortium, researchers are developing solutions to repair joint defects, primarily in the knee, through regenerative medicine. These efforts are carried out within the Osteoarthritis (OA) Moonshot and supported by the broader infrastructure of the RegMed XB Pilot Factory, one of the largest international infrastructures for regenerative medicine.